SCHEMBL4633299

SCHEMBL4633299

COc1ccc(O)c(CC(C)O)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.47
GABRA1 P14867 2/20 0.47
GABRB2 P47870 2/20 0.47
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47
GAA P10253 3/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46
MCL1 Q07820 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 1/20 0.46
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16013328 0.87 GABRA1 (0.59) HTR2AGABRA1GABRB2MTNR1AMTNR1B
SCHEMBL29066447 0.84 HTR2A (0.46) HTR2AGABRA1GABRB2MTNR1AMTNR1B
SCHEMBL4630564 0.83 ABCB11 (0.46) GABRA1GABRB2MAPTLMNA
SCHEMBL3458869 0.82 HTR2A (0.47) HTR2AGAA
SCHEMBL3459047 0.82 HTR2A (0.70) HTR2AGABRA1GABRB2GAA
SCHEMBL13692380 0.82 HTR2A (0.70) HTR2AGABRA1GABRB2GAA
SCHEMBL3458865 0.82 HTR2A (0.47) HTR2AGAA
SCHEMBL17571961 0.81 HTR2A (0.46) HTR2AGAAALDH1A1
SCHEMBL4121937 0.80 ERN1 (0.50) HTR2AMTNR1AMTNR1BGAAKDM4E
SCHEMBL8959159 0.79 GAA (0.50) MTNR1AMTNR1BGAAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3355889-A1 DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH Afferent Pharmaceuticals Inc. (US) 2018-08-08 EP disclosed
EP-3164132-A1 METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS Afferent Pharmaceuticals Inc. (US) 2017-05-10 EP disclosed
EP-3035932-A1 DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH Afferent Pharmaceuticals Inc. (US) 2016-06-29 EP disclosed
WO-2016004358-A1 METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS Afferent Pharmaceuticals, Inc. (US) 2016-01-07 WO disclosed
WO-2015027212-A1 DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH AFFERENT PHARMACEUTICALS INC. (US) 2015-02-26 WO disclosed
EP-1926716-A1 PROCESS FOR SYNTHESIS OF ARYLOXY DIAMINOPYRIMIDINES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-04 EP disclosed
EP-1924264-A1 DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025898-A1 PROCESS FOR SYNTHESIS OF ARYLOXY DIAMINOPYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
WO-2007025925-A1 DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
EP-1725540-A1 DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-11-29 EP disclosed
WO-2005095359-A1 DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-13 WO disclosed